This expansion by Jindawei, a well-known entity in the nutrition and health industry, indicates a strategic move to vertically integrate their health product portfolio
It is different from TB-500 Research Peptide, different from GHRH analogues and different from metabolic receptor agonists
The Cs reflects how frequently the two events are reported together in the literature and is categorized as follows: [] = very high, [] = high, and [] = moderate. Scores corresponding to quite low [] and low [] were not found in this dataset
Validating the quality, compliance, and enforcement risk profile of portfolio companies in this space is not a formality
Under the circumstances, our MR study, theoretically with minimal reverse causation biases and no heterogeneity and horizontal pleiotropy existing, enjoys an advantage over them